JAML and colorectal carcinoma: Immunohistochemistry revealed that 50% (25/50) of CRC patients exhibited high JAML expression, primarily localized in the cytoplasm and membranes of cancer cells, with minimal expression in stromal immune cells and negligible levels in adjacent normal tissues.